Deltasonamide 2 (TFA) is primarily utilized in pharmaceutical research and development, particularly in the study of neurodegenerative diseases. It acts as a potent inhibitor of specific enzymes involved in the pathological processes of conditions like Alzheimer's and Parkinson's diseases. Researchers employ this compound to investigate its efficacy in modulating enzyme activity, which could potentially slow disease progression. Additionally, it is used in biochemical assays to understand the molecular mechanisms underlying neurodegeneration, aiding in the discovery of novel therapeutic targets. Its application extends to preclinical studies, where it is tested for safety and efficacy in animal models, providing critical data for potential drug development.